Figure 1.
Schematic structure of conbercept.
VEGF receptor-1 and receptor-2 are related receptors that have seven extracellular Ig domain plus an intracellular tyrosine kinase domain. Conbercept contains the Ig domain 2 of VEGF receptor-1 fused to the Ig domain 3 and 4 of VEGF receptor-2 fused to the IgG1 Fc.
Figure 2.
The binding efficiency comparison of conbercept and Avastin with VEGF isoforms and PlGF by ELISA.
Conbercept present in figure by using an alias as KH902.
Figure 3.
The Dynamic Curves of VEGF inhibitors with VEGF isoforms and PlGF detected by BIACORE.
VEGF isoforms and PlGF were set as ligands to be immobilized onto the CM5 chips. Different VEGF inhibitors were set as analytes and two-fold diluted into six or eight concentrations. (A) conbercept with VEGF-A165 (B) conbercept with VEGF-A121. (C) Avastin with VEGF-A165. (D) Avastin with VEGF-A121. (E) conbercept with VEGF-B167. (F) conbercept with PlGF.
Table 1.
The detected kinetics constants comparison of different VEGF inhibitors with VEGF isoforms and PlGF.
Figure 4.
Endothelial Cell Proliferation Assay of conbercept and Avastin.
Figure 5.
FFA results of Hypoxic ischemic retinopathy Suppression Experiments.
Heavy leakages were observed indicating OIR models successfully established (the arrow pointing in the Figure 5B). Less leakage and fewer neovasularizations were observed in OIR models treated with conbercept (the arrow pointing in the Figure 5C). (A) Negative control group. (B) Model control group. (C) Medicated group.
Table 2.
The numbers of vascular endothelial cells beyond the inner limiting membrane ().
Figure 6.
The growth dynamics of LOVO in nude mice.
The tumor volume was measured weekly through 6 weeks. The figure showed the mean TV per group at different time points after tumor implantation. Group1: normal saline (NS). Group 2–4: conbercept at 2, 6 and 18 mg/kg, respectively. Group5: 6 mg/kg Avastin. Group 6: 5-FU at 50 mg/kg. Group 7: 5-FU (50 mg/kg) and conbercept (6 mg/kg). (A) Tumor volume in each group. (B) The mean tumor weights at the end of experiment. (C) Anti-tumor rates (%).